一品红(300723.SZ)：子公司获得磷酸奥司他韦胶囊药品补充申请批准通知书

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for its Oseltamivir Phosphate Capsules, indicating a significant development in its product portfolio and potential market opportunities in influenza treatment and prevention [1] Group 1: Product Approval - The company’s wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted a "Drug Supplement Application Approval Notice" for Oseltamivir Phosphate Capsules [1] - The approved indications for the drug include treatment for adults and children aged 1 year and older for both Type A and Type B influenza, with effective treatment if administered within 48 hours of symptom onset [1] - The drug is also approved for the prevention of Type A and Type B influenza in adults and adolescents aged 13 years and older [1] Group 2: Product Specifications - The company currently offers the drug in two dosages: 75 mg and 45 mg [1]